In:
Infectious Diseases in Clinical Practice, Ovid Technologies (Wolters Kluwer Health), Vol. 29, No. 2 ( 2021-3), p. e82-e87
Abstract:
Outpatient parenteral antimicrobial therapy (OPAT) has been safely used to treat a variety of infections. However, limited data are available on the safety and efficacy of OPAT for central nervous system (CNS) infections. Methods This was a retrospective, single-center study evaluating the safety and efficacy of OPAT in patients with CNS infections between July 1, 2009, and May 31, 2016. Demographic, medical, infection-specific, and drug-specific data were collected for each patient. Patients were categorized as clinical cure, probable cure, or treatment failure based on resolution or recurrence of infection for up to 1 year after OPAT completion. Safety of OPAT was evaluated through adverse drug event (ADE) and line complication (LC) monitoring. Readmission rates from OPAT-related ADE and LC were also recorded. Results Forty-seven patients with CNS infections (mean age, 45.3 years; 70.2% male) received OPAT for a median duration of 12 days (range, 2–144 days); 1 patient was excluded from efficacy analysis because of hospice transition. Thirty-seven patients (80.4%) achieved clinical cure, 7 patients (15.2%) had probable cure, and 2 patients (4.3%) experienced treatment failure. Three patients (6.4%) experienced ADE and 4 patients (8.5%) experienced LC during OPAT. Five patients (10.6%) required rehospitalization because of worsening infection (n = 1), LC (n = 2), cerebrospinal fluid leak repair (n = 1), and insurance issues (n = 1). Six patients (12.8%) required a therapy change because of ADE or LC. Conclusions Treating CNS infections with OPAT seems to be safe and effective based on the low failure and complication rates observed in this study.
Type of Medium:
Online Resource
ISSN:
1536-9943
,
1056-9103
DOI:
10.1097/IPC.0000000000000933
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2021
detail.hit.zdb_id:
2062211-9
